0001516513-22-000082.txt : 20221110 0001516513-22-000082.hdr.sgml : 20221110 20221110162802 ACCESSION NUMBER: 0001516513-22-000082 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Doximity, Inc. CENTRAL INDEX KEY: 0001516513 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING SERVICES [7371] IRS NUMBER: 272485512 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40508 FILM NUMBER: 221377708 BUSINESS ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (650) 549-4330 MAIL ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 8-K 1 docs-20221110.htm 8-K docs-20221110
0001516513FALSE00015165132022-11-102022-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2022
_________________________________________________________________________________________________________________
Doximity, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________________________________________________________________________________________________
Delaware001-4050827-2485512
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
500 3rd St.
Suite 510
San Francisco, CA 94107
(Address of principal executive offices, including zip code)
(650) 549-4330
(Registrant's telephone number, including area code)
_______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, $0.001 par value per shareDOCSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02 – Results of Operations and Financial Condition
On November 10, 2022, Doximity, Inc. (“Doximity”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
The information provided in this Item 2.02 of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberDescription
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 10, 2022
DOXIMITY, INC.
By:
/s/ Anna Bryson
Anna Bryson
Chief Financial Officer


EX-99.1 2 doximity-2022930xex991.htm EX-99.1 Document

Exhibit 99.1
Doximity Announces Fiscal 2023 Second Quarter Financial Results
Q2 total revenues of $102.2 million, up 29% year-over-year
Q2 operating cash flow of $39.5 million, up 106% year-over-year
Q2 free cash flow of $37.7 million, up 109% year-over-year

SAN FRANCISCO, Calif., November 10, 2022 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2023 second quarter ended September 30, 2022.
“We were pleased to beat on both our top and bottom lines while delivering our first nine-figure revenue quarter,” said Jeff Tangney, co-founder and CEO at Doximity. “Our telehealth platform grew to a record 370,000 quarterly active clinicians. We will continue to invest in building tools to help physicians save time, so they can provide better care for their patients.”
Fiscal 2023 Second Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended September 30, 2021.
Revenue: Revenue of $102.2 million, versus $79.4 million, an increase of 29% year-over-year.
Net income and non-GAAP net income: Net income of $26.3 million, versus $36.1 million, representing a margin of 26%, versus 45%. Non-GAAP net income of $36.2 million, versus $41.6 million, representing a margin of 35%, versus 52%.
Adjusted EBITDA: Adjusted EBITDA of $46.0 million, versus $32.8 million, an increase of 40% year-over-year, representing adjusted EBITDA margins of 45%, versus 41%.
Net income per share and non-GAAP net income per share: Diluted net income per share was $0.12, versus $0.17, while non-GAAP diluted net income per share was $0.17, versus $0.19.
Operating cash flow and free cash flow: Operating cash flow of $39.5 million, versus $19.2 million, and free cash flow of $37.7 million, versus $18.1 million.
Financial Outlook
Doximity is providing guidance for its fiscal third quarter ending December 31, 2022 as follows:
Revenue between $110.7 million and $111.7 million.
Adjusted EBITDA between $47.7 million and $48.7 million.
Doximity is reiterating its guidance for its fiscal year ending March 31, 2023 as follows:
Revenue between $424.0 million and $432.0 million.
Adjusted EBITDA between $178.0 million and $186.0 million.
Stock Repurchase Program
The board of directors of Doximity authorized another program to repurchase up to $70 million of the Company’s Class A common stock. The repurchases are expected to be executed from time to time over the next 12 months, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans.

1


Conference Call Information
Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of the COVID-19 pandemic (including the impact to our industry or on our customers’ industries, impact on general economic conditions, and government responses, restrictions, and actions related to the pandemic); (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Annual Report on Form 10-K that was filed with the SEC on May 27, 2022. Additional information will be provided in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
Perry Gold
ir@doximity.com
Media Contact:
Amanda Cox
pr@doximity.com




2


DOXIMITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
September 30, 2022March 31, 2022
Assets
Current assets:
Cash and cash equivalents$73,674 $112,809 
Marketable securities676,317 685,304 
Accounts receivable, net 79,236 81,073 
Prepaid expenses and other current assets15,691 19,439 
Deferred contract costs, current2,999 5,512 
Total current assets847,917 904,137 
Property and equipment, net11,647 8,488 
Deferred income tax assets50,583 48,558 
Operating lease right-of-use assets14,894 1,087 
Intangible assets, net34,232 7,909 
Goodwill67,940 18,915 
Other assets1,130 2,263 
Total assets$1,028,343 $991,357 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,106 $463 
Accrued expenses and other current liabilities26,408 25,270 
Deferred revenue, current89,616 84,907 
Operating lease liabilities, current1,013 642 
Total current liabilities118,143 111,282 
Deferred revenue, non-current166 78 
Operating lease liabilities, non-current14,625 447 
Contingent earn-out consideration liability, non-current15,422 — 
Other liabilities, non-current1,023 956 
Total liabilities149,379 112,763 
Stockholders' Equity
Preferred stock— — 
Common stock192 192 
Additional paid-in capital730,582 702,589 
Accumulated other comprehensive loss(21,559)(15,294)
Retained earnings169,749 191,107 
Total stockholders' equity878,964 878,594 
Total liabilities and stockholders’ equity$1,028,343 $991,357 

3


DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
Revenue$102,185 $79,350 $192,824 $152,019 
Cost of revenue(1)
13,210 8,951 26,287 16,937 
Gross profit88,975 70,399 166,537 135,082 
Operating expenses(1):
Research and development19,104 15,460 38,126 28,701 
Sales and marketing29,021 21,161 57,155 40,532 
General and administrative8,749 8,827 17,473 16,023 
Total operating expenses56,874 45,448 112,754 85,256 
Income from operations32,101 24,951 53,783 49,826 
Other income, net908 420 1,712 465 
Income before income taxes33,009 25,371 55,495 50,291 
Provision for (benefit from) income taxes6,710 (10,717)6,813 (12,119)
Net income$26,299 $36,088 $48,682 $62,410 
Undistributed earnings attributable to participating securities— — — (18,326)
Net income attributable to Class A and Class B common stockholders, basic and diluted$26,299 $36,088 $48,682 $44,084 
Net income per share attributable to Class A and Class B common stockholders:
Basic$0.14 $0.19 $0.25 $0.32 
Diluted$0.12 $0.17 $0.23 $0.27 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic193,137 186,171 193,042 137,154 
Diluted213,949 216,672 214,452 166,066 
(1) Costs and expenses include stock-based compensation expense as follows:
Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
Cost of revenue$2,392 $793 $4,514 $1,061 
Research and development2,862 1,859 5,414 2,829 
Sales and marketing3,982 1,866 7,056 2,894 
General and administrative2,117 2,154 3,875 5,015 
Total stock-based compensation expense$11,353 $6,672 $20,859 $11,799 
4


DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
Cash flows from operating activities
Net income$26,299 $36,088 $48,682 $62,410 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization2,589 1,158 4,959 2,311 
Deferred income taxes— — 105 — 
Stock-based compensation, net of amounts capitalized11,353 6,672 20,859 11,799 
Non-cash lease expense551 286 952 569 
Amortization of premium on marketable securities, net1,218 1,264 2,673 1,561 
Loss (gain) on sale of marketable securities463 (72)500 (70)
Amortization of deferred contract costs2,072 2,452 4,839 5,656 
Other37 288 195 
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable(3,339)(9,978)2,194 (5,556)
Prepaid expenses and other assets2,405 (14,867)3,651 (17,728)
Deferred contract costs(1,476)(1,483)(2,342)(2,975)
Accounts payable, accrued expenses and other liabilities1,635 1,478 (4,474)(780)
Deferred revenue(4,280)(3,967)1,872 (4,427)
Operating lease liabilities(13)(167)(211)(638)
Net cash provided by operating activities39,514 19,152 84,266 52,327 
Cash flows from investing activities
Cash paid for acquisition— — (53,500)— 
Purchases of property and equipment(766)(200)(1,476)(241)
Internal-use software development costs(1,051)(900)(2,466)(1,671)
Purchases of marketable securities(82,307)(1,088,768)(91,177)(1,156,143)
Maturities of marketable securities16,167 24,787 24,438 35,551 
Sales of marketable securities49,434 531,076 64,158 531,076 
Net cash used in investing activities(18,523)(534,005)(60,023)(591,428)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering after deducting underwriting discounts and commissions— — — 553,905 
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants2,570 2,323 5,584 5,060 
Proceeds from issuance of common stock in connection with the employee stock purchase plan2,341 — 2,341 — 
Taxes paid related to net share settlement of equity awards(1,152)(56)(1,261)(56)
Repurchase of common stock(61,168)— (70,042)(2,698)
Payments of deferred offering costs— (2,214)— (3,982)
Net cash provided by (used in) financing activities(57,409)53 (63,378)552,229 
Net increase (decrease) in cash and cash equivalents(36,418)(514,800)(39,135)13,128 
Cash and cash equivalents, beginning of period110,092 594,321 112,809 66,393 
Cash and cash equivalents, end of period
$73,674 $79,521 $73,674 $79,521 

5


Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and expenses associated with acquisitions from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics1
Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
Customers with trailing 12-month subscription revenue greater than $100,000: The number of customers with TTM subscription revenue greater than $100,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $100,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity.
1 The metric excludes the impact of the AMiON acquisition, which closed on April 1, 2022, including customers of, and subscription revenue generated from, the AMiON on-call scheduling and messaging application and was immaterial to the periods presented.
6


Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
(unaudited)
(in thousands, except percentages)
Net income$26,299 $36,088 $48,682 $62,410 
Adjusted to exclude the following:
Acquisition and other related expenses— — 30 — 
Stock-based compensation11,353 6,672 20,859 11,799 
Depreciation and amortization2,589 1,158 4,959 2,311 
Provision for (benefit from) income taxes6,710 (10,717)6,813 (12,119)
Change in fair value of contingent earn-out consideration liability(40)— (94)— 
Other income, net(908)(420)(1,712)(465)
Adjusted EBITDA$46,003 $32,781 $79,537 $63,936 
Revenue$102,185 $79,350 $192,824 $152,019 
Net income margin26 %45 %25 %41 %
Adjusted EBITDA margin45 %41 %41 %42 %

Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
(unaudited)
(in thousands)
Net cash provided by operating activities$39,514 $19,152 $84,266 $52,327 
Purchases of property and equipment(766)(200)(1,476)(241)
Internal-use software development costs(1,051)(900)(2,466)(1,671)
Free cash flow$37,697 $18,052 $80,324 $50,415 
Other cash flow components:
Net cash used in investing activities$(18,523)$(534,005)$(60,023)$(591,428)
Net cash provided by (used in) financing activities$(57,409)$53 $(63,378)$552,229 
7


Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
(unaudited)
(in thousands, except per share data and percentages)
GAAP cost of revenue$13,210 $8,951 $26,287 $16,937 
Adjusted to exclude the following:
Stock-based compensation(2,392)(793)(4,514)(1,061)
Amortization of acquired intangibles(137)— (273)— 
Non-GAAP cost of revenue$10,681 $8,158 $21,500 $15,876 
GAAP gross profit$88,975 $70,399 $166,537 $135,082 
Adjusted to exclude the following:
Stock-based compensation2,392 793 4,514 1,061 
Amortization of acquired intangibles137 — 273 — 
Non-GAAP gross profit$91,504 $71,192 $171,324 $136,143 
GAAP gross margin87 %89 %86 %89 %
Non-GAAP gross margin90 %90 %89 %90 %
GAAP research and development expense$19,104 $15,460 $38,126 $28,701 
Adjusted to exclude the following:
Stock-based compensation(2,862)(1,859)(5,414)(2,829)
Non-GAAP research and development expense$16,242 $13,601 $32,712 $25,872 
GAAP sales and marketing expense$29,021 $21,161 $57,155 $40,532 
Adjusted to exclude the following:
Stock-based compensation(3,982)(1,866)(7,056)(2,894)
Amortization of acquired intangibles(1,061)(265)(2,124)(530)
Change in fair value of contingent earn-out consideration liability40 — 94 — 
Non-GAAP sales and marketing expense$24,018 $19,030 $48,069 $37,108 
GAAP general and administrative expense$8,749 $8,827 $17,473 $16,023 
Adjusted to exclude the following:
Acquisition and other related expenses— — (30)— 
Stock-based compensation(2,117)(2,154)(3,875)(5,015)
Non-GAAP general and administrative expense$6,632 $6,673 $13,568 $11,008 
GAAP operating expense$56,874 $45,448 $112,754 $85,256 
Adjusted to exclude the following:
Acquisition and other related expenses— — (30)— 
Stock-based compensation(8,961)(5,879)(16,345)(10,738)
Amortization of acquired intangibles(1,061)(265)(2,124)(530)
Change in fair value of contingent earn-out consideration liability40 — 94 — 
Non-GAAP operating expense$46,892 $39,304 $94,349 $73,988 
8


Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
(unaudited)
(in thousands, except per share data and percentages)
GAAP operating income$32,101 $24,951 $53,783 $49,826 
Adjusted to exclude the following:
Acquisition and other related expenses— — 30 — 
Stock-based compensation11,353 6,672 20,859 11,799 
Amortization of acquired intangibles1,198 265 2,397 530 
Change in fair value of contingent earn-out consideration liability(40)— (94)— 
Non-GAAP operating income$44,612 $31,888 $76,975 $62,155 
GAAP net income$26,299 $36,088 $48,682 $62,410 
Adjusted to exclude the following:
Acquisition and other related expenses— — 30 — 
Stock-based compensation11,353 6,672 20,859 11,799 
Amortization of acquired intangibles1,198 265 2,397 530 
Change in fair value of contingent earn-out consideration liability(40)— (94)— 
Income tax effect of non-GAAP adjustments (1)
(2,627)(1,457)(4,870)(2,589)
Non-GAAP net income$36,183 $41,568 $67,004 $72,150 
Non-GAAP net income margin35 %52 %35 %47 %
GAAP undistributed earnings attributable to participating securities$— $— $— $(18,326)
Impact on undistributed earnings attributable to participating securities due to non-GAAP adjustments— — — (2,055)
Non-GAAP undistributed earnings attributable to participating securities$— $— $— $(20,381)
Non-GAAP net income$36,183 $41,568 $67,004 $72,150 
Non-GAAP undistributed earnings attributable to participating securities— — — (20,381)
Non-GAAP net income attributable to Class A and Class B stockholders, basic and diluted$36,183 $41,568 $67,004 $51,769 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic193,137 186,171 193,042 137,154 
Diluted213,949 216,672 214,452 166,066 
Non-GAAP net income per share attributable to Class A and Class B stockholders:
Basic$0.19 $0.22 $0.35 $0.38 
Diluted$0.17 $0.19 $0.31 $0.31 
(1) For the three and six months ended September 30, 2022 and 2021, management used an estimated annual effective non-GAAP tax rate of 21.0%.
9
EX-101.SCH 3 docs-20221110.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 docs-20221110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 docs-20221110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 10, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 10, 2022
Entity Registrant Name Doximity, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40508
Entity Tax Identification Number 27-2485512
Entity Address, Address Line One 500 3rd St.
Entity Address, Address Line Two Suite 510
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94107
City Area Code 650
Local Phone Number 549-4330
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.001 par value per share
Trading Symbol DOCS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001516513
Amendment Flag false
XML 7 docs-20221110_htm.xml IDEA: XBRL DOCUMENT 0001516513 2022-11-10 2022-11-10 0001516513 false 8-K 2022-11-10 2022-11-10 Doximity, Inc. DE 001-40508 27-2485512 500 3rd St. Suite 510 San Francisco CA 94107 650 549-4330 false false false false Class A common stock, $0.001 par value per share DOCS NYSE true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.doximity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports docs-20221110.htm docs-20221110.xsd docs-20221110_lab.xml docs-20221110_pre.xml doximity-2022930xex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "docs-20221110.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "docs-20221110.htm" ] }, "labelLink": { "local": [ "docs-20221110_lab.xml" ] }, "presentationLink": { "local": [ "docs-20221110_pre.xml" ] }, "schema": { "local": [ "docs-20221110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "docs", "nsuri": "http://www.doximity.com/20221110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20221110.htm", "contextRef": "ieb7fb9900ab84573bc92861c0d191df8_D20221110-20221110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.doximity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20221110.htm", "contextRef": "ieb7fb9900ab84573bc92861c0d191df8_D20221110-20221110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001516513-22-000082-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516513-22-000082-xbrl.zip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end